Glasgow, Scotland, UK—8 November 2017—
ISPOR, the professional society for health economics and outcomes research (HEOR), held an important discussion on the challenges inherent in assessing new antibiotics in a world facing the growing threat of antibiotic resistance. The issue panel was held this morning at ISPOR’s
20th Annual European Congress in Glasgow, Scotland, UK.
The issue panel, “
How Can We Assess the Value of New Antibiotics?” [IP22], was moderated by Chris Henshall, PhD, Office of Health Economics, London, UK. Speakers included Alec Morton, PhD, University of Strathclyde, Glasgow, Scotland, UK; Douglas Lundin, PhD, TLV (Swedish Dental and Pharmaceutical Reimbursement Agency), Stockholm, Sweden; and Adrian Towse, MA, MPhil, Office of Health Economics, London, UK.
In this session, speakers explored the challenges assessors have in evaluating new antibiotics that are beginning to come to market following international initiatives designed to boost research and development in response to the urgent need for new antibiotics. Speakers discussed the need for health technology assessment and payer bodies to be able to assess the value of these new antibiotics so that prices and payment mechanisms can provide both appropriate access for patients and return-on-investment for developers.
Adrian Towse, MA, MPhil presented work from the Office of Health Economics on developing a value framework for antibiotics, building on a recent discussion forum in London with key stakeholders. Alec Morton, PhD provided an update on the findings of the DRIVE-AB project (funded by the European Commission and EFPIA), which aims to provide an approach for the assessment of the value of an antibiotic. Douglas Lundin, PhD reflected on the challenges for payers, health systems, and governments and the ways that these challenges can be addressed.
Additional information on the ISPOR 20th Annual European Congress can be found
here. Released presentations from the congress can be found
here. Interested parties can follow news and developments from the congress on social media using the hashtag
#ISPORGlasgow.
###
ABOUT ISPOR
ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.
Web:
www.ispor.org | LinkedIn:
http://bit.ly/ISPOR-LIn | Twitter:
http://bit.ly/ISPOR-T (@ISPORorg) | YouTube:
http://bit.ly/ISPOR-YT | Facebook:
http://bit.ly/ISPOR-FB